GlaxoSmithKline's Laval facilities become North American head office for vaccine research and development



    
    A $50M initiative supported by the Biotech City, Montréal International
    -----------------------------------------------------------------------
                             and Montréal InVivo
                             -------------------
    

    MONTREAL, June 11 /CNW Telbec/ - The Biotech City, Montréal International
and Montréal InVivo applauded GlaxoSmithKline's (GSK) decision to invest
$50 million in its Laval facilities to develop a brand-new North American head
office for vaccine research and development. The three organizations have
actively supported this initiative and helped bring the large-scale project to
fruition.
    "GSK's decision to invest in its Laval facilities speaks to the vitality
of the Biotech City and the synergy that exists between the Institut
Armand-Frappier and the private sector companies located in the vicinity,"
said Mr. Robert Dubé, Director General of the Laval Technopole and President
and CEO of the City of Biotechnology and Human Health of Metropolitan
Montréal.
    "This is an important decision that will help strengthen Greater
Montréal's position as a world leader in life sciences, in addition to
boosting its role in the manufacturing of new vaccines," said Mr. André
Gamache, Executive Vice President of Montréal International. "This investment
also reflects the metropolitan business climate, which, increasingly, is
fostering research and innovation, two drivers of the knowledge economy and of
Greater Montréal's economic prosperity," he added.
    "By banking on research and innovation, GSK supports the cluster's
efforts to make the region an area that is recognized on the world stage for
the quality of its researchers and the excellence of its innovative businesses
and institutions in the life sciences field," said Mr. Carl Viel, General
Manager of Montréal InVivo, Greater Montréal's Life Sciences cluster.
    To facilitate the completion of this major expansion project in Greater
Montréal, several partners teamed up, including the Biotech City, Montréal
International and Montréal InVivo, which provided the pharmaceutical company
with the support it needed, starting in the fall of 2005. "Companies like GSK
are a driving force in our economy and contribute to the region's prosperity.
With our partners, we work daily to support the competitiveness and appeal of
Greater Montréal," said Mr. Gamache.
    A true hub for R&D, Greater Montréal ranks first among all metropolitan
regions in Canada in terms of funds dedicated to university research and the
number of research centres and researchers.
    GlaxoSmithKline is one of the largest R&D companies in Canada. Every
year, it allocates over $100 million to this sector, making it one of the
20 companies investing the most in R&D in the country. On an international
level, the company spends more than $5 billion on R&D annually.

    About the Biotech City (www.citebiotech.com)

    The Biotech City was created around the Institut national de la recherche
scientifique, research centers and a critical mass of biotech and
biopharmaceutical companies, including a number of world leaders in their
respective fields. It also boasts an exceptional accommodation capacity
bolstered by highly attractive tax incentives for companies that choose to
locate in the Biotech City. The City of Biotechnology and Human Health of
Metropolitan Montréal is located on one million square meters of land in
Laval, at the heart of an innovative university and business network.

    About Montréal International (www.montrealinternational.com)

    Montréal International was created in 1996 as a result of a
private/public partnership. Its mission is to contribute to the economic
development of Metropolitan Montréal and to enhance its international status.
Montréal International is funded by the private sector, the Communauté
métropolitaine de Montréal, the City of Montréal, and the governments of
Canada and Québec. Its mandates include attracting foreign investment,
international organizations and strategic workers, and supporting the
development of competitive clusters in the high-technology sectors.

    About Montréal InVivo (www.montreal-invivo.com)

    The Montréal InVivo cluster endeavours to establish conditions enabling
the life sciences industry to make a significant contribution to the economic
and social vitality of Greater Montréal. Its mission is to identify levers
that can accelerate the development of life sciences in the region, and to
work as a network to position the cluster among the world's leaders in the
sector.




For further information:

For further information: Céline Clément, Communications Advisor,
Montréal International, (514) 987-9390,
celine.clement@montrealinternational.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890